Q-omics provides the consensus-scored ADCY6 profile across patient tissues and cancer cell-line models. ADCY6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ADCY6 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ADCY6 RNA expression shows 20,521 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, LIHC, and KIRP as cancer lineages where ADCY6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADCY6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADCY6 survival associations across molecular data types. ADCY6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADCY6 RNA expression–survival associations across cancer types. High ADCY6 expression shows unfavorable associations in CESC, LIHC, LGG and LUAD, but favorable associations in UVM and STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ADCY6 RNA expression.
This table summarizes ADCY6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADCY6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADCY6 shows lower tumor expression in COAD, HNSC, LUSC, KICH and BRCA and higher tumor expression in LIHC. The LIHC box plot shows higher ADCY6 RNA expression in tumor versus normal tissue (log2 FC = +2.002, t-test p < 0.001).
This table shows molecular features associated with ADCY6 in patient tissues and cancer cell lines. In patient samples, ADCY6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ADCY6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
